[{"orgOrder":0,"company":"Point Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Series A Financing","leadProduct":"PNT2002","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Point Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Bach Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"PNT2004","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ Point Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Point Biopharma"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Avacta Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Pro-doxorubicin","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Point Biopharma \/ Point Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Point Biopharma"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"CanProbe","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Lutetium\u2013177 Octreotate","moa":"SSRT2","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ Point Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Point Biopharma"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"PNT2001","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ Point Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Point Biopharma"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"177Lu-PNT2004","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Kinectrics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Ytterbium-176","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ Point Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Point Biopharma \/ Point Biopharma"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Ionetix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"PNT2001","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Point Biopharma \/ Ionetix","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Ionetix"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Belgian Nuclear Research Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"PNT2002","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Point Biopharma \/ Belgian Nuclear Research Center","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Belgian Nuclear Research Center"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"177Lu-PNT6555","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"177Lu-PNT2004","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lu-177-PSMA-I&T","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Piper Sandler"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Piper Sandler"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"177Lu-PNT6555","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Lantheus Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":2.1200000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2.1200000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Point Biopharma \/ Lantheus Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Lantheus Holdings"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Lantheus Holding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":2.1200000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2.1200000000000001,"dosageForm":"","sponsorNew":"Point Biopharma \/ Lantheus Holding","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Lantheus Holding"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Eckert & Ziegler Strahlen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"PNT2001","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ Point Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Point Biopharma"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Lantheus Holding","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Lantheus Holding","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Lantheus Holding"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"AdvanCell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"212Pb-ADVC001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Point Biopharma \/ Point Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Point Biopharma \/ Point Biopharma"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Point Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Point Biopharma"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Athebio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"DARPin-targeted Radioligand","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ Point Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Point Biopharma \/ Point Biopharma"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":1.3999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.3999999999999999,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Eli Lilly"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":1.3999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.3999999999999999,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Eli Lilly"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Lantheus Holding","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Not Applicable","leadProduct":"[Lu-177]-PNT2002","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ Point Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Point Biopharma"}]

Find Clinical Drug Pipeline Developments & Deals by Point Biopharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : Through the acquisition, Lilly expands its oncology capabilities into next-generation radioligand therapies by including PNT2002 (177Lu-PNT2002), a PSMA targeted radioligand therapy in development for patients with metastatic castration-resistant prostat...

Product Name : PNT2002

Product Type : Small molecule

Upfront Cash : $1,400.0 million

December 27, 2023

Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Eli Lilly

Deal Size : $1,400.0 million

Deal Type : Acquisition

blank

02

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy under phase 3 clinical development for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.

Product Name : [Lu-177]-PSMA-I&T

Product Type : Undisclosed

Upfront Cash : Not Applicable

December 18, 2023

Lead Product(s) : [Lu-177]-PNT2002

Therapeutic Area : Oncology

Highest Development Status : Phase III

Recipient : Lantheus Holding

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : Through the acquisition, Lilly expands its oncology capabilities into next-generation radioligand therapies by including PNT2002 (177Lu-PNT2002), a PSMA targeted radioligand therapy in development for patients with metastatic castration-resistant prostat...

Product Name : PNT2002

Product Type : Small molecule

Upfront Cash : $1,400.0 million

October 03, 2023

Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Eli Lilly

Deal Size : $1,400.0 million

Deal Type : Acquisition

blank

04

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : The collaboration aims to develop and commercialize DARPin in the radioligand therapy field. The parties will collaborate in discovery, candidate selection and preclinical development of Athebody® DARPins for use as Radio-DARPin drug entities.

Product Name : Undisclosed

Product Type : Small molecule

Upfront Cash : Undisclosed

September 18, 2023

Lead Product(s) : DARPin-targeted Radioligand

Therapeutic Area : Oncology

Highest Development Status : Discovery

Recipient : Athebio

Deal Size : Undisclosed

Deal Type : Collaboration

blank

05

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : The expanded agreement broadens the supply of ITM’s n.c.a. 177Lu to POINT to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in POINT’s development pipeline, including 177Lu-PNT2002 for prosta...

Product Name : PNT2002

Product Type : Small molecule

Upfront Cash : Undisclosed

July 31, 2023

Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

Therapeutic Area : Oncology

Highest Development Status : Phase III

Recipient : Isotope Technologies Munich

Deal Size : Undisclosed

Deal Type : Agreement

blank

06

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : The collaboration aims on the development of a global 212Pb radioisotope and radioligand supply chain to specifically support the development and commercialization of 212Pb-labeled radioligands including, 212Pb-ADVC001, a best-in-class treatment for meta...

Product Name : 212Pb-ADVC001

Product Type : Small molecule

Upfront Cash : Undisclosed

June 26, 2023

Lead Product(s) : 212Pb-ADVC001

Therapeutic Area : Oncology

Highest Development Status : Phase I

Recipient : AdvanCell

Deal Size : Undisclosed

Deal Type : Collaboration

blank

07

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.

Product Name : PNT2002

Product Type : Large molecule

Upfront Cash : Not Applicable

April 24, 2023

Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Lantheus Holding

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

08

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : Under the agreement, Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT’s pipeline of next generation Ac-225-based radioligands, including PSMA-targeted PNT2001 program.

Product Name : PNT2001

Product Type : Large molecule

Upfront Cash : Undisclosed

April 04, 2023

Lead Product(s) : PNT2001

Therapeutic Area : Oncology

Highest Development Status : Preclinical

Recipient : Eckert & Ziegler Strahlen

Deal Size : Undisclosed

Deal Type : Agreement

blank

09

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.

Product Name : PNT2002

Product Type : Large molecule

Upfront Cash : Not Applicable

January 12, 2023

Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

10

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.

Product Name : PNT2002

Product Type : Large molecule

Upfront Cash : $260.0 million

December 20, 2022

Lead Product(s) : Lutetium (177Lu) Zadavotide Guraxetan

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Lantheus Holdings

Deal Size : $2,115.0 million

Deal Type : Agreement

blank